Home › Myelofibrosis › California
Myelofibrosis clinical trials in California
21 studies for Myelofibrosis are looking for participants at sites in California.
Cities in California
- Baldwin Park9 studies
- Mountain View7 studies
- Los Angeles6 studies
- Irvine5 studies
- Sacramento3 studies
- Orange3 studies
- San Diego3 studies
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- City of Hope, Duarte
- University of Southern California, Los Angeles
- Hoag Family Cancer Institute, Newport Beach
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT04176198A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
- UCLA Ronald Reagan Medical Center, Los Angeles
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07469891A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
- Los Angeles Cancer Network, Glendale
- Cancer and Blood Specialty Clinic, Whittier
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07623161A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
- Stanford Cancer Institute Palo Alto, Palo Alto
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06661915Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- City of Hope - Duarte, Duarte
- City of Hope - Lennar, Irvine
- UCLA, Los Angeles
- and 1 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT05320198A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
- Stanford Cancer Institute, Palo Alto
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT06343805TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
- Stanford University, Palo Alto
RecruitingPhase 1
Ages 18 to 80 · All sexes · Updated Aug 17, 2026 · NCT07302776A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
- Stanford University, Palo Alto
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT07008118A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- City of Hope Medical Center, Duarte
RecruitingPhase 1Healthy volunteers welcome
Ages 18 to 75 · All sexes · Updated Jul 28, 2026 · NCT07020533Study of INCA036978 in Participants With Myeloproliferative Neoplasms
- City of Hope-Lennar Foundation Cancer Center, Irvine
- Usc Norris Comprehensive Cancer Center, Los Angeles
- UCLA Medical Hematology & Oncology, Los Angeles
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT07441694A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis
- City of Hope Center, Duarte
- UC Davis Comprehensive Cancer Center, Sacramento
- UC San Diego Moores Cancer Center, San Diego
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 20, 2026 · NCT07250646Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated May 4, 2026 · NCT07281781A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- City of Hope Medical Center, Duarte
- Stanford Cancer Institute, Palo Alto
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 17, 2026 · NCT06034002Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Mar 27, 2026 · NCT06063486A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- City of Hope, Duarte
- Stanford, Palo Alto
RecruitingPhase 2
Ages 18 to 66 · All sexes · Updated Mar 17, 2026 · NCT06859424CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
- City of Hope Medical Center, Duarte
RecruitingPhase 2Healthy volunteers welcome
Ages 18 to 75 · All sexes · Updated Mar 10, 2026 · NCT06059391An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
- University of California, Irvine, Irvine
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Mar 10, 2026 · NCT05123365A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
- City of Hope - Duarte Main Site, Duarte
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 12, 2026 · NCT05980806SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Duarte
- Massive Bio SYNERGY-AI site, Irvine
- Massive Bio SYNERGY-AI site, La Jolla
- and 3 more
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- UC San Diego Moores Cancer Center, La Jolla
- UCLA Hematology/Oncology Clinic - Los Angeles, Los Angeles
- Scripps Health, Prebys Cancer Center, San Diego
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2025 · NCT06479135Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
- UC Davis Health, Sacramento
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 13, 2025 · NCT05423691From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.